The regulatory basis for essential documents
Explore ICH E6(R3), FDA regulations, and EMA requirements that establish essential document obligations for sponsors, investigators, and institutions.
The morning everything changed
It is 6:47 AM on a Thursday in late October, and Dr. Sarah Chen is reviewing her email before rounds at Riverside Medical Center in Portland, Oregon. Between the usual administrative noise, one message stops her cold. The subject line reads: "FDA BIMO Inspection Notification - Protocol RVS-2024-ONC."
Sarah has been a principal investigator for fourteen years. She has navigated monitor visits, audit findings, and countless data clarifications. But this is different. This is the FDA's Bioresearch Monitoring Program announcing a for-cause inspection of her Phase 2 oncology trial, triggered by a safety signal that emerged during the sponsor's aggregate data review.